AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12728198
Drug: Psychiatric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric treatment administered by five psychiatrists on an outpatient basis for one year.
Trial: 12728198
Drug: As-usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-usual treatment from primary care physicians.
Trial: 12728198
Drug: Psychiatric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric treatment elsewhere (not specified).
Trial: 12728198
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (psychiatric treatment).
Trial: 10591045
Drug: Topical acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acetylsalicylic acid
Trial: 2128228
Drug: Phosphatidylserine (PS)
RxNorm normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylserine (PS) 400 mg/daily
Trial: 3158243
Drug: Tubocurarine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubocurarine 0.05 mg/kg
Trial: 906784
Drug: Gallamine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallamine 0.3 mg/kg
Trial: 30488093
Drug: External Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External Physical Vibration Lithecbole (EPVL) therapy
Trial: 30488093
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no EPVL therapy)
Trial: 28666965
Drug: Individualized antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized antibiotic duration (discontinued 48 hours after clinical stability, with at least five days of total antibiotic treatment)
Trial: 28666965
Drug: Standard antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotic duration
Trial: 28666965
Drug: Individualized antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized antibiotic duration
Trial: 26003508
Drug: MDMA (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (25, 50, 100 mg)
Trial: 26003508
Drug: Cannabis (THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis (THC 300 µg/kg)
Trial: 26003508
Drug: Cocaine (HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (HCl 300 mg)
Trial: 23052987
Drug: Caspofungin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (50 mg or 70/50 mg loading dose on Day 1)
Trial: 23052987
Drug: Micafungin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (150 mg)
Trial: 21967254
Drug: Tacrolimus (n=11)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (n=11) with steroids for 5 days and azathioprine (1 mg/kg) if WBC ≥ 4000 cells/cm³
Trial: 21967254
Drug: Sirolimus (n=10)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus (n=10) with steroids for 5 days and azathioprine (1 mg/kg) if WBC ≥ 4000 cells/cm³
Trial: 9669421
Drug: Fractional excretion
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional excretion of creatinine
Trial: 7752827
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 treatment for 4 weeks
Trial: 2456618
Drug: Aggressive combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive combined modality treatment (ProMACE-MOPP + TNI)
Trial: 25039577
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B CrossAction Power electric toothbrush
Trial: 29313577
Drug: Risorine (Rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risorine (Rifampicin 200 mg + Isoniazid 300 mg + Piperine 10 mg)
Trial: 29313577
Drug: Conventional anti-TB
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anti-TB therapy
Trial: 25450635
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (one subcutaneous injection/week for 4 weeks) in addition to standard protocol therapy (systemic pulse corticosteroids/cyclophosphamide with sulphasalazine and pentoxifylline)
Trial: 25450635
Drug: Standard protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protocol therapy (systemic pulse corticosteroids/cyclophosphamide with sulphasalazine and pentoxifylline)
Trial: 7508742
Drug: L-thyroxine tablet
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-thyroxine tablet (150 micrograms)
Trial: 7508742
Drug: L-thyroxine solution
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-thyroxine solution (150 micrograms)
Trial: 28710563
Drug: Morphine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine administered intravenously
Trial: 26259519
Drug: GS‐4997 (apoptosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS‐4997 (apoptosis signal‐regulating kinase 1 inhibitor)
Trial: 21931019
Drug: TASQ 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TASQ 0.25 mg/d escalating to 1.0 mg/d over 4 weeks
Trial: 18248654
Drug: Esomeprazole 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 80 mg intravenous bolus infusion for 30 min followed by esomeprazole 8 mg/h intravenously for 71.5 h
Trial: 18248654
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion for 72 h
Trial: 18248654
Drug: Esomeprazole 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 80 mg intravenous bolus infusion followed by esomeprazole 8 mg/h intravenously
Trial: 16449416
Drug: Interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal psychotherapy (IPT) plus pill‐placebo
Trial: 16449416
Drug: Interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal psychotherapy (IPT) plus citalopram (20 to 40 mg per day)
Trial: 16449416
Drug: Standardized clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized clinical management (CM) plus pill‐placebo
Trial: 16449416
Drug: Standardized clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized clinical management (CM) plus citalopram (20 to 40 mg per day)
Trial: 8739093
Drug: Dipyrone 3
RxNorm normalized name: dipyrone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 3 g/day
Trial: 8739093
Drug: Dipyrone 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 1.5 g/day
Trial: 8739093
Drug: Paracetamol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1.5 g/day
Trial: 7008184
Drug: 0.44 g
RxNorm normalized name: MENTHOL 0.44 g in 100 g / ZINC OXIDE 21 g in 100 g TOPICAL OINTMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.44 g acetylsalicylic acid (ASA)
Trial: 7008184
Drug: 3.96 g
RxNorm normalized name: Avobenzone 2.088 g in 60 mL / HOMOSALATE 2.838 g in 60 mL / OCTISALATE 3.041 g in 60 mL / OCTOCRYLENE 1.733 g in 60 mL / OXYBENZONE 3.96 g in 60 mL TOPICAL CREAM [hope in a jar broad spectrum spf 25 sunscreen and moisturizer for all skin types]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.96 g acetylsalicylic acid (ASA)
Trial: 30550301
Drug: CC (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC (control condition)
Trial: 8251778
Drug: 5,6‐benzo‐alpha‐pyrone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,6‐benzo‐alpha‐pyrone (200 mg tablets, two daily)
Trial: 15958399
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets daily)
Trial: 2870876
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg loprazolam
Trial: 31757794
Drug: Pioglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone treatment for 12 weeks
Trial: 31757794
Drug: Troglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone treatment of cultured human adipocytes
Trial: 29733520
Drug: Mango consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mango consumption (300 g for 4 weeks)
Trial: 24161369
Drug: Liquid barium
RxNorm normalized name: barium
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid barium thickened with a starch‐based agent (STARCH)
Trial: 24161369
Drug: Liquid barium
RxNorm normalized name: barium
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid barium thickened with a gum‐based agent (GUM)
Trial: 18190615
Drug: Low-residue diet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-residue diet, placebo fibre supplement, and loperamide
Trial: 18190615
Drug: Fibre supplement,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre supplement, neutral diet, and loperamide
Trial: 15864137
Drug: Topical calcipotriol
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcipotriol treatment
Trial: 12645717
Drug: Combined system
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined system (heparin-coated, centrifugal pump, closed circuit)
Trial: 1804598
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g twice a day i.v.
Trial: 1804598
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g once daily i.v.
Trial: 30057058
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Swedish massage and preferred music
Trial: 26650825
Drug: Wait-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list control group (received the program before the second chemotherapy cycle)
Trial: 23146636
Drug: Moderate-to-severe pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-to-severe pain during injection
Trial: 20491987
Drug: One-visit root
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-visit root canal treatment (n = 43)
Trial: 20491987
Drug: Two-visit root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-visit root canal treatment (n = 46)
Trial: 19253522
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (80% of patients)
Trial: 19253522
Drug: Monotherapy (20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (20% of patients)
Trial: 16012079
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of racemic lansoprazole
Trial: 12945829
Drug: HMBCr (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMBCr (3 g/d HMB, 3 g/d Cr)
Trial: 11012004
Drug: Sterile moisturizer
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sterile moisturizer and sterile cleanser used in combination, applied once or twice daily for 28 days
Trial: 8711553
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (0.4 g/kg/day for 5 days)
Trial: 8711553
Drug: Placebo (similar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (similar volume daily for 5 days)
Trial: 2005562
Drug: Ultrasound anterior
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound anterior capsule cleaning
Trial: 22011265
Drug: Clindamycin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 40 mg/kg/24 h
Trial: 22011265
Drug: First-generation cephalosporin
RxNorm normalized name: First-generation cephalosporins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation cephalosporin 150 mg/kg/24 h
Trial: 17509246
Drug: Biological markers
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological markers
Trial: 16089138
Drug: Fuzheng quxie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzheng quxie granule (FQG) + conventional western medicine (WM)
Trial: 16089138
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medicine (WM) alone
Trial: 7843696
Drug: 28 weeks
RxNorm normalized name: migalastat
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 28 weeks of natural IFN‐alpha treatment
Trial: 7843696
Drug: 52 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 52 weeks of natural IFN‐alpha treatment
Trial: 2146903
Drug: 20 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml/kg compound sodium lactate solution
Trial: 2146903
Drug: 20 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml/kg compound sodium lactate solution + 1 g/kg dextrose
Trial: 83088
Drug: 2% erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% erythromycin base in hydroalcoholic solution + 0.05% tretinoin solution
Trial: 83088
Drug: 2% erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% erythromycin base in hydroalcoholic solution
Trial: 29874199
Drug: LactoWise® (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LactoWise® (4.5 billion live cells of bacillus coagulans and galactomannans, 300 mg)
Trial: 29874199
Drug: Placebo (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (600 mg of calcium citrate yielding 126 mg of elemental calcium)
Trial: 23500237
Drug: Ranolazine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (target dose 1000 mg bid)
Trial: 17461854
Drug: TMC114/r (600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC114/r (600/100 mg bid)
Trial: 17461854
Drug: TPV/r (500/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPV/r (500/200 mg bid)
Trial: 12089852
Drug: Analgesic, hormonal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic, hormonal, and surgical treatment
Trial: 9642607
Drug: gemeprost 1
RxNorm normalized name: Gemeprost 1 mg vaginal pessary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemeprost 1 mg 3 hourly for 5 doses
Trial: 9642607
Drug: misoprostol 200
RxNorm normalized name: MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: misoprostol 200 mcg 6 hourly for 4 doses
Trial: 7661175
Drug: Nabumetone, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone, 1 g, b.i.d.
Trial: 7661175
Drug: Naproxen, 500
RxNorm normalized name: Naproxen, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen, 500 mg, b.i.d.
Trial: 905127
Drug: Digoxin 20
RxNorm normalized name: digoxin 200 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 20 microgram/kg/day (loading dose of 20 microgram/kg followed by maintenance dose of 7 microgram/kg every 8 hours)
Trial: 905127
Drug: Digoxin levels
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin levels exceeding 5 ng/ml
Trial: 28712113
Drug: Receiving tuberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving tuberculosis treatment
Trial: 26158605
Drug: Testosterone solution
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone solution 2% (60 mg applied to the axillae for 16 weeks)
Trial: 22067312
Drug: Adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dose (AD) of mycophenolate mofetil (MMF) using therapeutic drug monitoring (TDM)
Trial: 22067312
Drug: Fixed-dose (FD)
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose (FD) regimen of mycophenolate mofetil (MMF)
Trial: 19421770
Drug: FloSeal (5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FloSeal (5,000 U/5 mL)
Trial: 19421770
Drug: Tabotamp (oxidized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabotamp (oxidized regenerated cellulose patch, 2.5 x 5 cm)
Trial: 15283801
Drug: Itraconazole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (5 mg/kg/day, continuous regimen, either as capsule or oral suspension)
Trial: 1958942
Drug: Three treatment
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three treatment regimes (behavioural approach to diet and weight gain coupled with individual and family psychotherapy)
Trial: 1958942
Drug: Three treatment
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three treatment regimes
Trial: 7053265
Drug: CTP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTP (cyclophosphamide 400 mg/m2/day orally X 5, teniposide 100 mg/m2 iv X 1, prednisolone 60 mg/m2/day orally X 5)
Trial: 7053265
Drug: COP (vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COP (vincristine 1.4 mg/m2 iv X 1; maximum, 2 mg, with the same cyclophosphamide and prednisolone doses)
Trial: 25342246
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (normothermic)
Trial: 25072757
Drug: Simplified Severe
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simplified Severe Sepsis Protocol (up to 4 L of IV fluids within 6 hours, guided by jugular venous pressure assessment, and dopamine and/or blood transfusion in selected patients)
Trial: 18047458
Drug: 30 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minutes daily stretch of the wrist and finger flexors five days a week for four weeks
Trial: 10420149
Drug: Bicalutamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (50 mg once daily) plus LHRHa (goserelin acetate 3.6 mg or leuprolide acetate 7.5 mg)
Trial: 10420149
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg three times daily) plus LHRHa (goserelin acetate 3.6 mg or leuprolide acetate 7.5 mg)
Trial: 7593526
Drug: Mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (600 mg) plus sulprostone (250 micrograms)
Trial: 19218542
Drug: d‐MPH‐ER 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐MPH‐ER 20 to 40 mg/d
Trial: 16052676
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IFN beta‐1a in combination with ribavirin (Group 2)
Trial: 12444323
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) regimen 1 starting with 3 IR tablets (n = 15)
Trial: 12444323
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) regimen 2 starting with 10 IR tablets (n = 16)
Trial: 12444323
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) regimen 3 starting with 30 IR tablets (n = 16)
Trial: 9635520
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) morphine tablets administered every 12 hours
Trial: 9635520
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) morphine
Trial: 4185887
Drug: Radioactive iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radioactive iodine (131)I therapy
Trial: 30203440
Drug: Bupivacaine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 50 mg with adrenaline 100 μg (BA-group, n = 14)
Trial: 29446060
Drug: Midazolam group
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam group (20 ml of bupivacaine hydrochloride 0.25% + midazolam 50 μg/kg in 2 ml saline 0.9%)
Trial: 29446060
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (20 ml of bupivacaine hydrochloride 0.25% + 2 ml saline)
Trial: 20170698
Drug: Non-Yokukansan (donepezil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Yokukansan (donepezil monotherapy)
Trial: 12472618
Drug: Lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine cream 5% applied for 20 min
Trial: 12472618
Drug: Lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine cream 5% applied for 30 min
Trial: 12472618
Drug: Lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine cream 5% applied for 45 min
Trial: 12472618
Drug: Base cream
RxNorm normalized name: U-Base Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base cream as placebo